Iopamiro 150 (Iopamidol)

Iopamidol contains iodine atoms that strongly absorb X‑ray photons. When injected intravenously, the iodine raises the radiodensity of the blood and extracellular fluid, creating a contrast difference between vascular or tissue compartments and surrounding structures. This differential attenuation allows imaging equipment to produce high‑resolution pictures of anatomical details.

The dose of Iopamiro 150 is determined by the prescribing physician based on the specific imaging study, patient size, renal function, and clinical need. The healthcare provider calculates the appropriate volume and concentration to achieve optimal contrast while minimizing risk.

Safety data for Iopamiro 150 in pregnancy are limited, and the product is classified as having an unknown pregnancy category. It should only be used when clearly needed and when the potential diagnostic benefit outweighs any possible risk to the fetus. Breastfeeding mothers should consult their physician, as the drug may be excreted in milk.

To order Iopamiro 150, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Iopamiro (iopamidol) is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. It provides comparable image quality to other low‑osmolality agents such as iohexol or iopromide, but with reduced incidence of discomfort and adverse reactions, making it a preferred choice for many diagnostic procedures.

Iopamiro 150 should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product reaches room temperature, it may be used within the time frame specified in the manufacturer’s labeling.

Iopamiro 150 is administered intravenously, typically via a power injector or manual bolus injection, depending on the imaging protocol. The injection rate and volume are selected by the radiologist or technologist to achieve optimal contrast enhancement for the specific diagnostic study.

The most serious risks include severe allergic reactions such as anaphylaxis, acute kidney injury especially in patients with pre‑existing renal impairment, and significant hypotension or cardiovascular collapse. Prompt recognition and management of these reactions are essential during and after administration.

Iopamiro 150 should be avoided in patients with a known hypersensitivity to iodinated contrast media, severe renal dysfunction (e.g., eGFR < 30 mL/min/1.73 m²), uncontrolled hyperthyroidism, or a history of severe allergic reactions to contrast agents. Clinicians must evaluate each patient’s risk factors before use.